



Independent Global Leader in Ophthalmic Innovation

Laboratoires Théa is a privately held, family-owned pharmaceutical company dedicated exclusively to eye care. Headquartered in Clermont-Ferrand, France, Théa builds on more than 150 years of ophthalmic expertise from the Chibret family. Its independent governance enables a long-term strategy focused on innovation, sustainable growth, and global expansion.

Innovation at the Core of the Strategy

Théa is internationally recognized as a pioneer of preservative-free ophthalmic treatments, having transformed industry standards with the development of ABAK® technology, the first multidose eye-drop system delivering sterile drops without preservatives.

Innovation is a structural pillar of the group:

- >10% of annual revenue reinvested in R&D
- Strong internal expertise combined with technology-driven product development
- Focus on patient-centric solutions and unmet clinical needs

Théa develops treatments across the full ophthalmology spectrum, including dry eye, glaucoma, Macular degeneration, allergy, infection, surgery, and rare eye diseases—ensuring portfolio resilience and multiple growth drivers.

Open Innovation & Strategic Partnerships

Théa operates a robust Open Innovation model designed to accelerate access to next-generation therapies and platforms.

Key pillars include:

- Strategic collaborations with biotech companies, academic centers, and clinical networks
- Co-development and licensing opportunities across early to late clinical stages
- Targeted investments in advanced therapeutic areas, including rare and orphan eye diseases
- Dedicated innovation structures supporting high-value scientific partnerships

This approach positions Théa as a preferred partner for innovators seeking industrial, clinical, and international scale-up capabilities.

Global Platform for Scalable Growth

- >2,200 employees worldwide
- Direct presence and distribution in 75 countries
- 100% European manufacturing, ensuring quality and supply reliability
- U.S. expansion via Thea Pharma Inc., established in 2019, strengthening access to the world's largest ophthalmology market

Théa's global footprint enables efficient commercialization and value maximization of innovative assets.

THÉAOPENINNOVATIONS.A.S. - CAPITAL DE 40 020 000 € - 843 953 829 RCS CLERMONT-FERRAND - TVA INTRACOM. FR91 843 953 829

12 RUE LOUIS BLÉRIOT - Z.I. DU BRÉZET - 63017 CLERMONT-FERRAND - CEDEX 2 - FRANCE

TÉL. +33 (0)4.73.98.14.36 - FAX +33 (0)4.73.98.14.24

www.theaopeninnovation.com